MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma